Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629663 | 1.00 | ALDH1A1 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL27412775 | 0.82 | MAPT (0.41) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL3181055 | 0.80 | CYP2C19 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL631049 | 0.80 | CYP2C19 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL28157325 | 0.80 | CYP2C19 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL26699486 | 0.80 | CYP2C19 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| Ammonia Solution, Strong SCHEMBL16982684 | 0.80 | MAPT (0.40) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL2053110 | 0.80 | CYP2C19 (0.38) | ALDH1A1LMNACYP2C19MAPTPOLB | |
| SCHEMBL2710202 | 0.79 | PKM (0.40) | ALDH1A1LMNAMAPT | |
| Ammonia Solution, Strong SCHEMBL16895224 | 0.78 | CYP2C19 (0.37) | ALDH1A1LMNACYP2C19MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096810-A1 | ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096810-A1 | ENANTIOSELECTIVE SYNTHESIS OF DIALKYLATED N,O-HETEROCYCLES BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ODC1, OSTC, AOC1 | ALDH1A1 561/4885LMNA 2884/4885CYP2C19 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.